Immix Biopharma (NASDAQ:IMMX – Get Free Report) will likely be announcing its earnings results on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter.
Immix Biopharma Stock Performance
IMMX opened at $1.95 on Thursday. The stock has a market capitalization of $53.64 million, a price-to-earnings ratio of -2.29 and a beta of 0.26. The company has a fifty day moving average of $1.88 and a 200 day moving average of $1.87. Immix Biopharma has a fifty-two week low of $1.26 and a fifty-two week high of $3.35.
Wall Street Analyst Weigh In
Separately, HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Immix Biopharma in a research note on Monday, February 10th.
About Immix Biopharma
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
Featured Stories
- Five stocks we like better than Immix Biopharma
- With Risk Tolerance, One Size Does Not Fit All
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- Health Care Stocks Explained: Why You Might Want to Invest
- Alphabet’s Officially In A Bear Market—Time To Buy?
- 3 REITs to Buy and Hold for the Long Term
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
